Respiratory Disease

Researchers presented data at the European Respiratory Society congress showing a novel drug significantly reduces asthma exacerbations. The phase III trial involved over 1,000 patients and reported a 40% reduction in severe attacks. Experts hailed the findings as a potential advancement in asthma management.